KM Pharmaceutical faces first KOSDAQ biotech delisting under 20 billion-won rule
AI Summary- KM Pharmaceutical entered the KOSDAQ delisting process after failing to restore its market capitalization.
- KM Pharmaceutical’s market capitalization stood at approximately 4.5 billion won when delisting was triggered.
- The Korea Exchange suspended trading on the 15th and scheduled delisting for the 29th.